101 related articles for article (PubMed ID: 8747986)
41. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL
Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
[TBL] [Abstract][Full Text] [Related]
42. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma.
Haas R; Brittinger G; Meusers P; Murea S; Goldschmidt H; Wannenmacher M; Hunstein W
Leukemia; 1996 Dec; 10(12):1975-9. PubMed ID: 8946940
[TBL] [Abstract][Full Text] [Related]
43. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
44. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery.
Dreger P; Viehmann K; von Neuhoff N; Glaubitz T; Petzoldt O; Glass B; Uharek L; Rautenberg P; Suttorp M; Mills B; Mitsky P; Schmitz N
Bone Marrow Transplant; 1999 Jul; 24(2):153-61. PubMed ID: 10455343
[TBL] [Abstract][Full Text] [Related]
45. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
46. High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients.
Mahendra P; Johnson D; Hood IM; Scott MA; Barker P; Bass G; Jestice HK; Bloxham DM; Boraks P; Wimperis JZ; Baglin TP; Marcus RE
Bone Marrow Transplant; 1996 Jun; 17(6):973-8. PubMed ID: 8807102
[TBL] [Abstract][Full Text] [Related]
47. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
48. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
49. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
[TBL] [Abstract][Full Text] [Related]
50. Mobilization/transplantation of peripheral blood progenitor cells for aggressive non-Hodgkin's lymphoma with marrow involvement.
Santini G; Congiu AM; Nati S; Pierluigi D; Spriano M; Chisesi T; Rossi E; Vimercati R; Sertoli MR; Figari O; Gobbi M; Piaggio G; Vassallo F; Benvenuto F; Soracco M; Miglino M; Bruni R; Ravetti JL; Truini M
Leukemia; 1996 Jun; 10 Suppl 2():s88-91. PubMed ID: 8649061
[TBL] [Abstract][Full Text] [Related]
51. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
[TBL] [Abstract][Full Text] [Related]
52. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Karcher A; Möhle R; Witt B; Goldschmidt H; Frühauf S; Flentje M; Wannenmacher M; Hunstein W
J Clin Oncol; 1994 Aug; 12(8):1685-92. PubMed ID: 7518860
[TBL] [Abstract][Full Text] [Related]
53. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients.
Fruehauf S; Schmitt K; Veldwijk MR; Topaly J; Benner A; Zeller WJ; Ho AD; Haas R
Br J Haematol; 1999 Jun; 105(3):786-94. PubMed ID: 10354148
[TBL] [Abstract][Full Text] [Related]
54. Autologous peripheral blood stem cell transplantation in hematological malignancies.
Teofili L; Sica S; Pierelli L; Menichella G; Paoloni A; Leone G; Bizzi B
Haematologica; 1990; 75 Suppl 1():70-3. PubMed ID: 1972132
[TBL] [Abstract][Full Text] [Related]
55. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma.
Haas R; Möhle R; Frühauf S; Goldschmidt H; Witt B; Flentje M; Wannenmacher M; Hunstein W
Blood; 1994 Jun; 83(12):3787-94. PubMed ID: 7515721
[TBL] [Abstract][Full Text] [Related]
56. Effects of erythropoietin on mobilisation of haemopoietic progenitor cells.
Pettengell R; Woll PJ; Chang J; Coutinho L; Testa NG; Crowther D
Bone Marrow Transplant; 1994 Jul; 14(1):125-30. PubMed ID: 7951099
[TBL] [Abstract][Full Text] [Related]
57. Side population cells in highly enriched CD34-positive cells from peripheral blood progenitor cells identify an immature subtype of hematopoietic progenitor cells but do not predict time to engraftment in patients treated with high-dose therapy.
Josefsen D; Forfang L; Dyrhaug M; Blystad AK; Stokke T; Smeland EB; Kvalheim G
Eur J Haematol; 2011 Dec; 87(6):494-502. PubMed ID: 21752097
[TBL] [Abstract][Full Text] [Related]
58. Rapid engraftment of peripheral blood progenitor cell grafts purged with B cell-specific monoclonal antibodies and immunomagnetic beads.
Dreger P; von Neuhoff N; Suttorp M; Löffler H; Schmitz N
Bone Marrow Transplant; 1995 Oct; 16(4):627-9. PubMed ID: 8528184
[TBL] [Abstract][Full Text] [Related]
59. Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time.
Pettengell R; Woll PJ; O'Connor DA; Dexter TM; Testa NG
Bone Marrow Transplant; 1994 Nov; 14(5):703-9. PubMed ID: 7889003
[TBL] [Abstract][Full Text] [Related]
60. High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose.
Lefrère F; Delarue R; Somme D; Levy V; Damaj G; Tu A; Porcher R; Audat F; Boulat C; Cavazzana-Calvo M; Buzyn A; Belanger C; Maillard N; Hermine O; Varet B
Transfusion; 2002 Apr; 42(4):443-50. PubMed ID: 12076291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
